What question did this study set out to answer?

The aim is to assess platelet recovery and its impact on survival in patients with myelofibrosis post-transplant.

January 17, 2026Haematologica0 citationsOpen Access

Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation

FSFederica Sora'Università Cattolica del Sacro Cuore ABA. BacigalupoUniversità Cattolica del Sacro Cuore SGsabrina giammarco

Key Points

The aim is to assess platelet recovery and its impact on survival in patients with myelofibrosis post-transplant.
Analyzed data from 93 patients with myelofibrosis
Measured platelet counts aiming for 50x10^9/L within day +100 post-transplant
Evaluated non-relapse mortality and actuarial survival rates
67% of patients achieved the target platelet count by day +100
Achieving this platelet count correlated with significantly lower non-relapse mortality (5% vs 55%; p=0.0009)
Patients reaching the target exhibited higher 5-year actuarial survival rates (85% vs 38%)

Abstract

We studied platelet recovery in 93 patients with myelofibrosis, following an allogeneic hemopoietic stem cell transplant (HSCT). The primary end point of the study was achieving a platelet count of 50x10⁹/L within day +100, which occurred in 62 patients (67%) and predicted 5 year non relapse mortality (5% vs 55%; p=0. 0009) and 5 year actuarial survival (85% vs 38%; p=

问 AI

Bookmark

View Full Paper